Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients-Reference-Cited by-同舟云学术

Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients

Published:2019-01-17 Issue:4 Volume:53 Page:1802107
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Ghimire Samiksha,Maharjan Bhagwan,Jongedijk Erwin M.,Kosterink Jos G.W.,Ghimire Gokarna R.,Touw Daan J.,van der Werf Tjip S.,Shrestha Bhabana,Alffenaar Jan-Willem C.

Funder

Rijksuniversiteit Groningen

Universitair Medisch Centrum Groningen

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference15 articles.

1. World Health Organization . Rapid Communication: Key changes to treatment of multi-drug and rifampicin- resistant tuberculosis (MDR/RR-TB) . www.who.int/tb/publications/2018/WHO_RapidCommunicationMDRTB.pdf?ua=1. Date last accessed: September, 2018. Date last updated: 2018.

2. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update;Falzon;Eur Respir J,2017

3. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

4. Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis

5. Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-08

2. Evaluation of therapeutic effectiveness of antituberculosis injection based on conversion time in drug-resistant tuberculosis;Pharmacia;2024-07-24

3. Levofloxacin-Induced Arthralgia in Multidrug-Resistant Tuberculosis Patients: A Case Series Spanning Three Age Groups;Cureus;2024-07-19

4. Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis;Infectious Diseases Now;2024-02

5. Pharmacokinetics and Safety of Group A and B Anti-Tuberculosis Drugs Used in Treatment of Rifampicin-Resistant Tuberculosis during Pregnancy and Post-Partum: A Narrative Review;Pathogens;2023-11-24